Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of “Moderate Buy” by Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been assigned an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $25.4444.

Several brokerages have recently weighed in on ARCT. Roth Mkm began coverage on shares of Arcturus Therapeutics in a report on Thursday, January 22nd. They issued a “buy” rating and a $20.00 target price on the stock. B. Riley Financial began coverage on shares of Arcturus Therapeutics in a report on Wednesday, March 18th. They set a “buy” rating and a $22.00 price objective on the stock. Piper Sandler decreased their price objective on shares of Arcturus Therapeutics from $72.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, March 4th. Citigroup decreased their price objective on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a “buy” rating on the stock in a report on Thursday, March 5th. Finally, Weiss Ratings raised shares of Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, April 21st.

Arcturus Therapeutics Stock Performance

Shares of Arcturus Therapeutics stock opened at $8.26 on Friday. The company has a market capitalization of $234.75 million, a P/E ratio of -2.94 and a beta of 2.43. The company’s fifty day moving average is $7.91 and its two-hundred day moving average is $7.60. Arcturus Therapeutics has a 1 year low of $5.85 and a 1 year high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.95) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.08. The business had revenue of $2.06 million for the quarter, compared to the consensus estimate of $6.30 million. Arcturus Therapeutics had a negative net margin of 143.80% and a negative return on equity of 36.55%. As a group, equities analysts expect that Arcturus Therapeutics will post -4.18 earnings per share for the current year.

Institutional Trading of Arcturus Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ARCT. Osaic Holdings Inc. boosted its holdings in Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after buying an additional 738 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Arcturus Therapeutics by 163.4% during the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after buying an additional 2,586 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in Arcturus Therapeutics during the fourth quarter worth about $64,000. Intech Investment Management LLC purchased a new stake in Arcturus Therapeutics during the fourth quarter worth about $70,000. Finally, CANADA LIFE ASSURANCE Co boosted its holdings in Arcturus Therapeutics by 65.1% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company’s stock worth $73,000 after buying an additional 4,737 shares in the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.